Conference Coverage

PRIDE study supports novel approach to ECT for geriatric depression


 

AT THE ECNP CONGRESS

A swipe at ECT’s critics

Dr. Kellner called ECT “a fabulous therapy,” albeit one with a serious image problem.

“I think the problem with ECT is not that we don’t know all the details of how it works or what it does clinically, it’s really a sociopolitical issue about ECT not being adequately accepted. I break down this lack of acceptance into two forms: The first is passive lack of acceptance based on our profession not having embraced ECT and continuing to fail to embrace it. The other is the active propaganda against ECT that is promulgated by the Church of Scientology, which has taken on a life of its own now because of the Internet. ECT is still fought by the Church of Scientology. They fund lots of people to say incorrect nasty things about ECT to inappropriately frighten our patients,” Dr. Kellner charged.

He cautioned that proposed new Food and Drug Administration regulations governing ECT devices would greatly limit the use of ECT, restricting it to adults with treatment-resistant major depressive disorder or bipolar disorder or who require a rapid response. Other currently cleared indications would become off-label uses.

“With off-label ECT, the potential problem is practitioners may not be covered by their malpractice insurance. And the bigger issue is health insurers may not pay for it unless the ECT is for an on-label indication,” Dr. Kellner said.

He shared that he has found extremely helpful a colleague’s advice to demystify ECT by inviting a family member to witness a patient’s treatment session. That witness can then testify to others that what goes on bears no resemblance to what happens to Jack Nicholson in the classic film “One Flew Over the Cuckoo’s Nest.”

The PRIDE study was funded by the National Institute of Mental Health. Dr. Kellner reported having no financial conflicts of interest.

Pages

Recommended Reading

Depression, PTSD double risk of dementia for older female veterans
MDedge Internal Medicine
Alcohol use, high-risk drinking increases in U.S. to ‘crisis’ levels
MDedge Internal Medicine
Cancer screening in elderly: When to just say no
MDedge Internal Medicine
Cognitive decline not seen with lower BP treatment targets
MDedge Internal Medicine
Fueling the Alzheimer’s brain with fat
MDedge Internal Medicine
Teriparatide reduces fractures over risedronate in all subgroups with osteoporosis
MDedge Internal Medicine
Early cognitive impairment associated with later Parkinson’s disease
MDedge Internal Medicine
Salmonella infections: The source may be as close as your patient’s backyard
MDedge Internal Medicine
Romosozumab reduces fracture risk out to 36 months, with no signs of cardiovascular problems
MDedge Internal Medicine
Higher BP targets suggested for elderly, cognitively impaired
MDedge Internal Medicine

Related Articles

  • Conference Coverage

    Data grow in support of ECT for depression

    Despite persistent stigma, data in support of various methods of the field’s most enduring treatment for depression continue to mount.